Helen Sabzevari
Known title: President and CEOCIK: 0001724195
Helen Sabzevari's purchase track record
Helen Sabzevari has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/27/2023 | PGEN | $40K | -26.2% | -15.8% | +12.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PGEN | ▲ Buy | Option Exercise | 20,833 | — | 8/23/2026 | View on chart |
| PGEN | ▼ Sell | Tax Withholding | 10,184 | $73K | 8/23/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 346,836 | $808K | 6/29/2026 | View on chart |
| PGEN | ▼ Sell | Open Market | 346,836 | $2.0M | 6/29/2026 | View on chart |
| PGEN | ▼ Sell | Open Market | 119,250 | $520K | 5/28/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 250,000 | — | 5/23/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 321,100 | — | 3/18/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 1,079,137 | — | 5/16/2025 | View on chart |
| PGEN | ▼ Sell | Tax Withholding | 521,224 | $756K | 5/16/2025 | View on chart |
| PGEN | ▲ Buy | Grant | 825,000 | $0 | 1/29/2025 | View on chart |
| PGEN | ▼ Sell | Tax Withholding | 286,967 | $373K | 1/29/2025 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 1,071,429 | — | 4/5/2024 | View on chart |
| PGEN | ▼ Sell | Tax Withholding | 410,357 | $574K | 4/5/2024 | View on chart |
| PGEN | ▼ Sell | Open Market | 76,969 | $118K | 8/25/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 141,587 | — | 8/23/2023 | View on chart |
| PGEN | ▼ Sell | Open Market | 55,855 | $93K | 8/18/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 141,587 | — | 8/16/2023 | View on chart |
| PGEN | ▼ Sell | Open Market | 41,436 | $60K | 8/11/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 141,587 | — | 8/9/2023 | View on chart |
| PGEN | ▼ Sell | Open Market | 52,870 | $58K | 8/4/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 141,587 | — | 8/2/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 283,173 | — | 3/24/2023 | View on chart |
| PGEN | ▲ Buy | Open Market | 22,857 | $40K | 1/27/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 17,665 | — | 1/4/2023 | View on chart |
| PGEN | ▼ Sell | Open Market | 177,968 | $211K | 5/13/2022 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 340,909 | — | 5/12/2022 | View on chart |
| PGEN | ▼ Sell | Open Market | 1,357 | $5K | 1/5/2022 | View on chart |
| PGEN | ▼ Sell | Open Market | 5,603 | $20K | 1/5/2022 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 17,667 | — | 1/4/2022 | View on chart |
| PGEN | ▼ Sell | Open Market | 3,848 | $14K | 1/3/2022 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 9,765 | — | 1/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Precigen mentioned in Zacks analyst blog
Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.
Precigen mentioned in Zacks analyst blog. Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.